TLR7 and neoplasm: Consistent with this hypothesis, a single dose of TransCon TLR7/8 Agonist in combination with systemic recombinant IL-2 resulted in greater anti-tumor activity in injected and non-injected tumors in an abscopal model, with mice bearing CT26 tumors on both flanks, compared to either single agent treatment alone (Fig. 6B).